BIOMAT Database Logo BIOMAT Database Logo

[CY 222, a very low molecular weight heparin, in the curative treatment of deep venous thrombosis. Apropos of 95 cases. Clinical and phlebographic results]. 1987

G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
Département d'Anesthésie-Réanimation I, Hôpital Pellegrin-Tripode, Bordeaux.

Efficacy of a very low molecular weight heparin, CY 222, in the treatment of deep venous thrombosis of lower limbs was evaluated in a prospective clinical trial instituted in November 1984. CY 222 was administered as subcutaneous injections of 0.03 ml.kg-1 daily (750 anti-Xa U.kg-1.d-1) as 3 divided doses over a minimum of 10 days. Efficacy was rated as a function of clinical and phlebographic criteria. The group of 95 patients treated was a heterogenious one: 38% medical, 62% surgical, and 48% of the total group had partial interruption of vena cava previous to study. The period between first clinical manifestations of the deep thrombosis and therapy varied between one day and 3 months (mean: 1 1/2 days). Clinical symptomatology significantly and globally regressed in 88% of the patients. Comparisons between phlebographic findings at start and end of treatment are expressed using Arnesen's score (cf. table).

UI MeSH Term Description Entries
D010690 Phlebography Radiographic visualization or recording of a vein after the injection of contrast medium. Venography,Phlebographies,Venographies
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013924 Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS). Phlegmasia Alba Dolens,Dolens, Phlegmasia Alba,Thrombophlebitides

Related Publications

G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
[Efficacy of a very low molecular weight heparin fragment (CY 222) compared to standard heparin in patients with deep venous thrombosis. A randomized study].
January 1987, Journal des maladies vasculaires,
G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
Low-molecular-weight heparin in the treatment of deep venous thrombosis.
October 1998, The Western journal of medicine,
G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
[The treatment of deep venous thrombosis with low-molecular-weight heparin].
January 1995, Revue medicale de Bruxelles,
G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
[Plasma exchange with very low molecular weight heparin CY 222. Biological profile and therapeutic value].
January 1988, Annales de medecine interne,
G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
Low-molecular-weight heparin for deep venous thrombosis.
November 1988, JAMA,
G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
Low-molecular-weight heparin for deep venous thrombosis.
September 1999, The Journal of family practice,
G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
[Use of a low molecular weight heparin, CY 222, in the treatment of consumption coagulopathy].
January 1987, Journal des maladies vasculaires,
G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
[Treatment of deep venous thrombosis with low molecular weight heparin (Fragmin)].
November 1991, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
[Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients)].
January 1990, La Revue de medecine interne,
G Janvier, and G Dugrais, and S Winnock, and C Vergnes, and M Boisseau, and J Broussin, and J M Serise, and P Boissieras, and J Videau, and F Toulemonde
Home treatment for deep venous thrombosis with low-molecular-weight heparin.
November 1988, Lancet (London, England),
Copied contents to your clipboard!